

Press Release

Lund, Sweden, May 7 2019

ImmuneBiotech: Winner of H2020 “SME Instrument” Phase 1

ImmuneBiotech Medical Sweden AB, the probiotic and microbiome company developing and marketing science-based probiotics, is pleased to announce it has received a Phase 1 grant of €50.000 from the European Innovation Council Horizon 2020 SME Instrument program.

The grant will be used to investigate the business feasibility of ImmuneBiotech’s probiotic product GutMagnific™ in Myalgic Encephalomyelitis, also called Chronic Fatigue Syndrome (ME/CFS). GutMagnific™ is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of Irritable Bowel Syndrome (IBS). The product also has potential in other conditions such as ME/CFS, which is a debilitating, multi system disease, characterized by unexplained persistent and relapsing fatigue and a combination of accompanying symptoms like IBS. The FDA has described this condition as “serious and life-threatening” with no current treatments. The global prevalence is between 0.2-1%, a higher prevalence than many chronic inflammatory conditions and cancer forms.

The EU selected ImmuneBiotech out of 2 822 applications based on criteria such as the high need for the innovation, a highly innovative solution that goes beyond the start of art, and the excellent experience of our team.

“I’m extremely pleased that ImmuneBiotech was selected by the European Commission. This is another external proof that our 15 years of experience in probiotics, immunology, microbiology and research on the gut-brain-axis is paying off in highly innovative probiotic products.” said Shahram Lavasani, CEO of ImmuneBiotech.

About ImmuneBiotech Medical AB

ImmuneBiotech discovers and markets science-based probiotic food supplements. Based on our multi-disciplinary scientific foundation, we deliver innovative probiotic products scientifically designed to modulate the gut microbiota, reduce gut permeability and reduce inflammation.

About GutMagnific™

GutMagnific™ is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patent pending combination of proprietary lactobacillus strains and will be sold as a food supplement supported by clinical data. GutMagnific™ has potential application in several other severe and prevalent conditions such as diarrhea, antibiotic induced diarrhea, *Clostridium difficile* infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). It has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).



About the European Commission's SME Instrument

The SME Instrument is part of the European Innovation Council (EIC) pilot that supports top-class innovators, entrepreneurs, small companies and scientists with funding opportunities and acceleration services.

Companies can apply for two distinct phases under the SME Instrument, depending on the maturity of their innovation. Under Phase 1 of SME Instrument, each project will receive a lump-sum of €50.000 to carry out a feasibility study. Under Phase 2, each project will receive from €0.5 to €2.5 million to finance innovation activities such as demonstration, testing, piloting and scaling up. In addition, companies under both phases can benefit from free coaching and business acceleration services.

For more information: <https://ec.europa.eu/easme/en/news/277-innovators-selected-funding-under-eic-s-sme-instrument>

Shahram Lavasani, CEO

ImmuneBiotech Medical AB
s.lavasani@immunebiotech.com
+46 707 40 86 61
www.immunebiotech.com